Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life
- 167 Downloads
Despite its importance, adherence to treatment has not been sufficiently studied in Behçet’s disease (BD). The aim of this study was to evaluate medication adherence in BD using the Compliance Questionnaire of Rheumatology (CQR) and factors potentially affecting it.
This cross-sectional study included 67 consecutive BD patients including 57 (85%) males with a mean age of 35.1 ± 9.27 years and mean disease duration of 129 ± 91 months. The cumulative clinical manifestations, the Behçet’s Disease Current Activity Form (BDCAF) score, and the Vasculitis Damage Index (VDI) were recorded. The CQR, Socioeconomic Status Questionnaire for Health Research in Egypt (SES), the Beliefs about Medication Questionnaire (BMQ), and the Short Form 36 (SF-36) quality of life assessment questionnaire were administered to the patients. Linear regression analysis was done to determine independent predictors of CQR.
The mean BDCAF score was 3.27 ± 3.54 and the VDI was 3.36 ± 2.21. The mean CQR score was 69.2 ± 11.79. The CQR score varied significantly among different health sources (p = 0.02), with no relationship detected with other sociodemographic characteristics, nor with clinical characteristics or the SF-36. Among the investigated medications’ complexities, severity of side effects showed significantly different CQR scores (p = 0.004), and a weak positive correlation between medications’ numbers and the CQR was detected. Predictors for higher CQR scores included the necessity beliefs score of the BMQ (β = 1.1, p < 0.001); whereas, predictors for lower CQR scores were the harm and concern BMQ subscales ((β = − 1.5, p = 0.004) and (β = − 0.72, p = 0.032), respectively).
Beliefs about medications were the only predictor for adherence in our cohort.
KeywordsAdherence Behçet’s disease Beliefs about medications Compliance Quality of life
Compliance with ethical standards
The study was approved by the local Ethics Committee, according to the provisions of the World Medical Association Declaration of Helsinki.
- 1.Behcet H (1937) Uber rezidivierende, aphthose durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalian. Dermatol Wochenschr 105:1152–1157Google Scholar
- 5.Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J (2015) A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther 32(11):983–1028. https://doi.org/10.1007/s12325-015-0256-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Voshaar M, Vriezekolk J, van Dulmen S, van den Bemt BJ, van de Laar M (2016) Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. BMC Musculoskelet. Disord 17(1):442. https://doi.org/10.1186/s12891-016-1289-z CrossRefGoogle Scholar
- 7.Khabbazi A, Karkon Shayan F, Ghojazadeh M, Kavandi H, Hajialiloo M, Esalat Manesh K, Kolahi S (2017) Adherence to treatment in patients with Behcet’s disease. Int J Rheum Dis. https://doi.org/10.1111/1756-185X.13109
- 13.Prudente LR, Diniz JS, Ferreira TXAM, Lima DM, Silva NA, Saraiva G, Silveira EA, Dewulf NLS, Amaral RG (2016) Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil. Patient Prefer Adherence 10:863–870. https://doi.org/10.2147/PPA.S79451 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Zhang L, Lu GH, Ye S, Wu B, Shen Y, Li T (2017) Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. Patient Preference Adherence 11:1591–1601. https://doi.org/10.2147/PPA.S144624 CrossRefPubMedGoogle Scholar
- 16.Bruce IN, Gladman DD, Urowitz MB (2000) Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence. Arthritis Care Res 13:406–408. https://doi.org/10.1002/1529-0131(200012)13:6<406::AID-ART11>3.0.CO;2-2 CrossRefPubMedGoogle Scholar
- 20.Cinar M, Cinar FI, Yilmaz S, Acikel C, Cakar M, Simsek I (2016) SAT0359 evaluation of medication compliance in Behcet’s disease. Ann Rheum Dis 75:797. https://doi.org/10.1136/annrheumdis-2016-eular.5266 CrossRefGoogle Scholar
- 21.Mumcu G, Alibaz-Öner F, Öner SY, Özen G, Atagündüz P, İnanç N, Köksal L, Ergun T, Direskeneli H (2017) Oral ulcer activity in Behcet’s disease: poor medication adherence is an underestimated risk factor. Eur J Rheumatol 4(2):109–112. https://doi.org/10.5152/eurjrheum.2017.160094 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, Al-Dalaan A, Alekberova ZS et al (2014) International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 28(3):338–347. https://doi.org/10.1111/jdv.12107 CrossRefGoogle Scholar
- 25.El-Gilany A, El-Wehady A, El-Wasify M (2012) Updating and validation of the socioeconomic status scale for health research in Egypt/Mise à jour et validation d’une échelle du statut socioéconomique pour la recherche en santé en Égypte. East Mediterr Health J 18(9):962–968CrossRefPubMedGoogle Scholar
- 27.Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380. https://doi.org/10.1002/art.1780400222 CrossRefPubMedGoogle Scholar
- 31.Alsous M, Alhalaiqa F, Abu Farha R, Abdel Jalil M, McElnay J, Horne R (2017) Reliability and validity of Arabic translation of Medication Adherence Report Scale (MARS) and Beliefs about Medication Questionnaire (BMQ)-specific for use in children and their parents. PloS One 12(2):e0171863. https://doi.org/10.1371/journal.pone.0171863 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Gottlieb H (2000) Medication nonadherence: finding solutions to a costly medical problem CME. Drug Benefit Trends 12(6):57–62Google Scholar
- 37.van den Bemt BJF, van den Hoogen FHJ, Benraad B, Hekster YA, van Riel PLCM, van Lankveld W (2009) Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 36(10):2164–2170. https://doi.org/10.3899/jrheum.081204 CrossRefPubMedGoogle Scholar
- 39.Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, Bruce IN (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology 54(10):1780–1791. https://doi.org/10.1093/rheumatology/kev105 CrossRefPubMedGoogle Scholar
- 40.de Thurah A, Nørgaard M, Harder I, Stengaard-Pedersen K (2010) Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheumatol Int 30(11):1441–1448. https://doi.org/10.1007/s00296-009-1160-8 CrossRefPubMedGoogle Scholar
- 41.Kuipers JG, Koller M, Zeman F, Mueller K, Rueffer JU (2017) THU0115 disability (HAQ) and quality of life (SF-12) as related to adherence and health literacy in patients with rheumatoid arthritis. Ann Rheum Dis 76:244. https://doi.org/10.1136/annrheumdis-2017-eular.5415 CrossRefGoogle Scholar